About Us

Endovascular Engineering, Inc. (“E2”), is a mission-driven, venture-backed company focused on the development and deployment of next generation clot removal technologies that target venous thromboembolism.

Leadership Team

Dan Rose
Dan Rose
Chief Executive Officer
Mike Rosenthal
Mike Rosenthal
Chief Operations Officer
Scott Baron
Scott Baron
Chief Technology Officer
Justin Farry
Justin Farry
Chief Financial Officer
Luis Savastano, MD, PhD
Luis Savastano, MD, PhD
Founder, Chief Scientific Officer
Thomas Engels
Thomas Engels
SVP Clinical and Market Development
Shane Johnson
Shane Johnson
SVP of Sales
Debra Cogan
Debra Cogan
VP of Clinical and Regulatory Affairs
Keri Ng
Keri Ng
VP of Quality
Dave Snow
Dave Snow
VP of Research and Development
Torsten Kimura
Torsten Kimura
VP of Manufacturing Operations
Lee Pusateri
Lee Pusateri
VP of Marketing

Key Clinical Partners

Eric Secemsky, MD, MSc
Eric Secemsky, MD, MSc
Interventional Cardiology
Jay Giri, MD, MPH
Jay Giri, MD, MPH
Interventional Cardiology
Andrew Klein, MD
Andrew Klein, MD
Interventional Cardiology
Julie Bulman, MD
Julie Bulman, MD
Interventional Radiology
Kush Desai, MD
Kush Desai, MD
Interventional Radiology

Key INVESTORS

Press Releases

07 Apr, 2026

E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves

19 Mar, 2026

Endovascular Engineering Announces Dual Late-Breaking Presentations at SIR and SCAI 2026 Highlighting Validation of Blood Return and Comprehensive ENGULF Study Results

03 Nov, 2025

E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference

02 Sep, 2025